PHAGE-BASED PRECISION ANTIMICROBIALS:
FAST AND EFFECTIVE
At Kinzbio, we create phage-based treatments and prevention solutions to tackle antibiotic-resistant infections. Our platform allows us to deliver (semi) personalized, pharmaceutical-grade therapies in just 5-15 days, based on the specific bacteria causing the patient’s infection.
We also develop solutions to prevent infections in hospitals and ICUs.
What sets us apart?
We combine patents, proprietary databases, biobanks and AI-driven software to identify and optimize phages for medical and industrial applications, giving us a strong advantage in precision antimicrobials.
Environmentally friendly: naturally safe for the environment.
ENVIRONMENTALLY
FRIENDLY
HIGHLY SPECIFIC
Targeting only the infection-causing bacteria while preserving beneficial microbes.
PERSONALIZED
Tailored to the specific needs of each patient
or process.
ADAPTABLE
Capable of adjusting to emerging challenges.​
Delivering solutions in just 5–15 days.
FAST
Our progress so far
SUCCESSFUL TREATMENTS
Successfully treated the first patients in Uruguay, achieving complete bacterial eradication after phage therapy for various medical conditions such as ventilator-associated pneumonia, urinary tract infections, and prosthetic joint infections.
SUPPORT
Our technology and strategy have received validation and support from esteemed international incubators and accelerators like INCATE and Eretz.Bio (Albert Einstein Hospital), which are aiding in our next steps.
REGULATORY DEVELOPMENT
We established a specific regulatory framework in collaboration with the local Ministry of Health, aligned with international regulations being developed in Europe and the U.S.
NEW OPORTUNITIES
We’re exploring new markets in Brasil, Europe and Colombia, where a team member is actively assessing business and commercialization prospects.
Antimicrobial
resistance is one
of the major global
health issues that
humanity is facing
Phages are natural
bacterial killers
that can be used to
combat AMR pathogens
In 2024 we began offering
phage therapy for clinical use, following approval from Uruguay's Ministry of Public Health
Every year millions
of lives are lost and
billions are spent in
prevention and
treatment of AMR
Kinzbio created an innovative
technology platform designed to develop phage-based precision antimicrobials for the treatment and prevention of infections caused by top-priority AMR pathogens.
​Unleashing the potential
of phages together
Kinzbio fosters collaborations and partnerships with pharma leaders, clinical organizations, academic labs and funding agencies to help the company to accelerate the development of its phage platform and pipeline.
Kinzbio has an open communication channel with and is always seeking to hear from industry partners and funding institutions interested in joining efforts to keep developing applications based on the biology of phages.
BE IN TOUCH
Please fill your contact details below
